Taken together, our findings identified the FFAR1 agonist TAK875 as a novel bronchoprotective agent that warrants further investigation to treat difficult-to-control asthma and/or airway hyperreactivity in obesity. The gene discussed is FFAR1; the disease is obesity due to melanocortin 4 receptor deficiency.